---
title: "Lineage Therap Expands ATM Equity Offering Capacity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278736148.md"
description: "Lineage Cell Therapeutics, Inc. has expanded its at-the-market equity offering capacity by filing a new prospectus supplement with the U.S. SEC, allowing it to sell an additional $60 million in common shares. This follows approximately $22.6 million previously sold, enhancing its financial flexibility for operations and growth. The current analyst rating for LCTX stock is a Hold with a $2.00 price target, reflecting concerns over financial performance despite an extended funding runway and operational milestones. Lineage focuses on developing cell-based therapies in the U.S. life sciences sector."
datetime: "2026-03-11T13:51:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278736148.md)
  - [en](https://longbridge.com/en/news/278736148.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278736148.md)
---

# Lineage Therap Expands ATM Equity Offering Capacity

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Lineage Therap ( (LCTX) ) has provided an announcement.

On March 11, 2026, Lineage Cell Therapeutics, Inc. filed a new prospectus supplement with the U.S. Securities and Exchange Commission to update its existing shelf registration, enabling ongoing at-the-market offerings of common shares through B. Riley Securities, Inc. Under this arrangement, the company may sell up to an additional $60 million of common shares, on top of roughly $22.6 million previously sold, expanding its capacity to raise equity capital over time and potentially strengthening its financial flexibility for operations and growth initiatives.

The most recent analyst rating on (LCTX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.

**Spark’s Take on LCTX Stock**

According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.

The score is held back primarily by weak financial performance driven by heavy losses and ongoing cash burn, despite low leverage. Offsetting this, the latest earnings call highlighted an extended funding runway and meaningful operational milestones, and technicals are supportive with price above major moving averages. Valuation remains constrained by lack of profitability and no dividend support.

To see Spark’s full report on LCTX stock, click here.

**More about Lineage Therap**

Lineage Cell Therapeutics, Inc. is a biotechnology company operating in the U.S. life sciences sector, focused on developing and commercializing cell-based therapies. Its primary activities center on advancing therapeutic candidates and accessing capital markets to fund research, development, and potential commercialization efforts.

**Average Trading Volume:** 1,180,423

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $450.8M

Find detailed analytics on LCTX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [LCTX.US](https://longbridge.com/en/quote/LCTX.US.md)

## Related News & Research

- [Top Executive Makes Bold Insider Move at Lineage Therap](https://longbridge.com/en/news/278988939.md)
- [CAI Marks Thirty Years Advancing Operational Readiness and Excellence Across Life Sciences and Mission-Critical Industries](https://longbridge.com/en/news/282541838.md)
- [Invivyd rises after update from late-stage trial for COVID therapy](https://longbridge.com/en/news/282283891.md)
- [Nancy T. Chang Discloses Investment at Galera Therapeutics with 5.9% Stake](https://longbridge.com/en/news/282371118.md)
- [Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround](https://longbridge.com/en/news/282567128.md)